Home » PARADIGM THERAPEUTICS ACQUIRES AMEDIS PHARMACEUTICALS AND SECURES NEW FINANCING TO ACCELERATE DRUG DISCOVERY
PARADIGM THERAPEUTICS ACQUIRES AMEDIS PHARMACEUTICALS AND SECURES NEW FINANCING TO ACCELERATE DRUG DISCOVERY
Paradigm Therapeutics has completed the acquisition of Amedis Pharmaceuticals, a medicinal chemistry and drug discovery company. The transaction will create an enlarged company with a unique mix of proprietary biology and chemistry capabilities. At merger, the company will have cash reserves of GBP11m, approximately half of which is new investment secured from existing investors, Bio*1Capital, Merlin Biosciences and Avlar BioVentures, on the back of the deal.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18622520&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct